Skip to main content
    A

    Anbio Biotechnology Class A Ordinary Shares (NNNN)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $3.88
    +0.06 (+1.57%)

    Market Cap: $167.66M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Anbio Biotechnology Class A Ordinary Shares (NNNN) Financials: Revenue, Profit and Cash Flow

    Updated Mar 31, 2026. Financial statements from company filings, amounts in US dollars.

    Anbio Biotechnology Class A Ordinary Shares reported revenue of $8.65M for the fiscal year ended Dec 31, 2025, up 5.6% from the year before. That year, net income was $6.40M with a net margin of 74.1%, operating cash flow was -$6.74M and free cash flow was -$6.74M. The quarter ended Mar 31, 2026 had revenue of $4.74M and net income of $3.04M.

    Revenue and Margins

    The operating margin was 66.7% in the fiscal year ended Dec 2025, the highest of the 5 years shown.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$8.65M+5.6%87.2%66.7%74.1%
    Dec 2024$8.19M+21.9%71.9%24.4%29.0%
    Dec 2023$6.71M-71.5%50.1%29.2%33.6%
    Dec 2022$23.54M+431.7%53.4%43.3%42.5%
    Dec 2021$4.43MN/A57.4%55.5%57.3%
    Annual, fiscal years ended Dec 2021 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 170.0% from the year before. In the quarter ended Mar 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Revenue$8.65M$8.19M$6.71M$23.54M$4.43M
    Cost of revenue$1.10M$2.30M$3.35M$10.98M$1.89M
    Gross profit$7.54M$5.89M$3.36M$12.56M$2.54M
    Research and development$201.31K$454.23K$134.70K$200.00K$0
    Operating income$5.77M$2.00M$1.96M$10.20M$2.46M
    Net income$6.40M$2.37M$2.25M$10.01M$2.54M
    EBITDA$5.77M$2.00M$2.27MN/A$2.54M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemMar 2026Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Revenue$4.74M$2.03M$5.01M-$3.13M$2.53M$1.17M$6.32M$2.92M$3.95M$1.83M$3.31M$1.53M
    Gross profit$3.86M$1.66M$4.62M-$2.60M$2.14M$987.38K$4.23M$1.96M$1.69M$781.92K$1.94M$898.51K
    Operating income$2.80M$1.20M$3.68M-$1.91M-$1.74M-$801.50K$3.89M$1.80M$583.74K$269.84K$1.54M$710.62K
    Net income$3.04M$1.30M$4.15M-$2.09M-$1.32M-$611.90K$3.89M$1.80M$792.93K$366.54K$1.64M$760.31K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $7.77M were 25.7% of total assets of $30.24M, against total liabilities of $87.84K.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Total assets$30.24M$18.92M$15.81M$13.96M$4.92M
    Current assets$30.24M$18.53M$15.75M$13.94M$4.92M
    Cash and equivalents$7.77M$11.76M$9.69M$7.10M$4.18M
    Total liabilities$87.84K$1.73M$993.06K$1.41M$2.38M
    Shareholder equity$30.16M$17.19M$14.82M$12.55M$2.54M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$30.24M$30.24M$30.24M$32.49M$27.68M$18.92M$18.92M$18.94M$18.94M$15.81M$15.81M$15.43M
    Total liabilities$87.84K$87.84K$87.84K$153.92K$131.13K$1.73M$1.73M$527.75K$527.75K$993.06K$993.06K$1.34M
    Cash and equivalents$7.77M$7.77M$7.77M$6.28M$5.35M$11.76M$11.76M$10.31M$10.31M$9.69M$9.69M$10.56M
    Shareholder equity$30.16M$30.16M$30.16M$32.34M$27.55M$17.19M$17.19M$18.42M$18.42M$14.82M$14.82M$14.09M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Operating cash flow-$6.74M$2.08M$898.37K$4.45M$4.18M
    Free cash flow-$6.74M$2.08M$898.37KN/A$4.18M
    Investing cash flow-$4.20M$337.10K$1.73M-$1.53MN/A
    Financing cash flow$6.95M-$344.61K-$42.84K$0N/A
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemMar 2026Sep 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flowN/AN/AN/A$1.60MN/A$647.54K$299.55K-$1.33M-$616.59KN/A$1.07M$3.36M
    Capital expenditures$0$0$0N/A$0N/A$0N/A$0N/A$0$4
    Free cash flowN/AN/AN/AN/AN/AN/A$299.55KN/A-$616.59KN/A$1.07M$3.36M
    Last 12 quarters

    Frequently Asked Questions About NNNN

    What is Anbio Biotechnology Class A Ordinary Shares' annual revenue?

    Anbio Biotechnology Class A Ordinary Shares reported revenue of $8.65M for the fiscal year ended Dec 31, 2025.

    How fast is Anbio Biotechnology Class A Ordinary Shares' revenue growing?

    Revenue was up 5.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -28.4%.

    Is Anbio Biotechnology Class A Ordinary Shares profitable?

    Yes. Anbio Biotechnology Class A Ordinary Shares reported net income of $6.40M for the fiscal year ended Dec 31, 2025, with a net margin of 74.1%.

    How much free cash flow does NNNN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$6.74M minus capital expenditures of $0 produced free cash flow of -$6.74M.

    How much debt does Anbio Biotechnology Class A Ordinary Shares have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $7.77M.